Literature DB >> 103492

Antimalarial activities of WR-194,965, an alpha-amino-o-cresol derivative.

L H Schmidt, R Crosby.   

Abstract

Pilot appraisals of the activities of WR-194,965 and WR-204,165, two closely related o-cresol derivatives (both Mannich bases), in owl monkeys infected with the multidrug-resistant Vietnam Smith strain of Plasmodium falciparum showed that these compounds had similar levels of efficacy. Total course doses effecting 90% cures (CD(90)s) were 27 and 37 mg/kg of body weight for the respective compounds, values almost identical to the CD(90) of mefloquine (a highly promising 4-quinolinemethanol) against infections with the same strain, and the CD(90)s of chloroquine against infections with 4-aminoquinoline-susceptible strains. Expanded studies of the activities of WR-194,965 against infections with the Smith strain of P. falciparum and Vietnam Palo Alto strain of P. vivax, designed to guide projected evaluations in human volunteers, showed: (i) that the activity of this compound was a function of total dose administered, with single doses as effective as the same amount delivered in three or seven successive daily fractions; (ii) that all regimens effected rapid clearance of parasitemia; and (iii) that based on CD(90)s, this agent was twice as active against infections with the Palo Alto strain of P. vivax as against the Smith strain of P. falciparum. These findings, together with results of preclinical pharmacological studies pursued elsewhere, provided support for studies in human volunteers now underway.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 103492      PMCID: PMC352533          DOI: 10.1128/AAC.14.5.672

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  A quinoline methanol (WR 30090) for treatment of acute malaria.

Authors:  D C Martin; J D Arnold; D F Clyde; M al-Ibrahim; P E Carson; K H Rieckmann; D Willerson
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

2.  Laboratory evaluation of the phototoxic potency of quinolinemethanols.

Authors:  W E Rothe; D P Jacobus
Journal:  J Med Chem       Date:  1968-03       Impact factor: 7.446

3.  Mefloquine (WR 142,490) in the treatment of human malaria.

Authors:  C M Trenholme; R L Williams; R E Desjardins; H Frischer; P E Carson; K H Rieckmann; C J Canfield
Journal:  Science       Date:  1975-11-21       Impact factor: 47.728

4.  Evaluating new antimalarial drugs against trophozoite induced Plasmodium cynomolgi malaria in rhesus monkeys.

Authors:  D E Davidson; D O Johnsen; P Tanticharoenyos; R L Hickman; K E Kinnamon
Journal:  Am J Trop Med Hyg       Date:  1976-01       Impact factor: 2.345

5.  Infections with Plasmodium falciparum and Plasmodium vivax in the owl monkey--model systems for basic biological and chemotherapeutic studies.

Authors:  L H Schmidt
Journal:  Trans R Soc Trop Med Hyg       Date:  1973       Impact factor: 2.184

6.  Plasmodium falciparum and Plasmodium vivax infections in the owl monkey (Aotus trivirgatus). III. Methods employed in the search for new blood schizonticidal drugs.

Authors:  L H Schmidt
Journal:  Am J Trop Med Hyg       Date:  1978-07       Impact factor: 2.345

7.  Antimalarial activities of various 4-quinolonemethanols with special attention to WR-142,490 (mefloquine).

Authors:  L H Schmidt; R Crosby; J Rasco; D Vaughan
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

8.  Plasmodium falciparum and Plasmodium vivax infections in the owl monkey (Aotus trivirgatus). II. Responses to chloroquine, quinine, and pyrimethamine.

Authors:  L H Schmidt
Journal:  Am J Trop Med Hyg       Date:  1978-07       Impact factor: 2.345

9.  Plasmodium falciparum and Plasmodium vivax infections in the owl monkey (Aotus trivirgatus). I. The courses of untreated infections.

Authors:  L H Schmidt
Journal:  Am J Trop Med Hyg       Date:  1978-07       Impact factor: 2.345

10.  The antimalarial properties of 2, 4-diamino-5-p-chlorophenyl-6-ethylpyrimidine, daraprim.

Authors:  L H SCHMIDT; C S GENTHER
Journal:  J Pharmacol Exp Ther       Date:  1953-01       Impact factor: 4.030

View more
  5 in total

1.  Characterization of the Preclinical Pharmacology of the New 2-Aminomethylphenol, JPC-3210, for Malaria Treatment and Prevention.

Authors:  Geoffrey W Birrell; Gavin D Heffernan; Guy A Schiehser; John Anderson; Arba L Ager; Pablo Morales; Donna MacKenzie; Karin van Breda; Marina Chavchich; Laura R Jacobus; G Dennis Shanks; David P Jacobus; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

2.  MK-4815, a potential new oral agent for treatment of malaria.

Authors:  Mary Ann Powles; John Allocco; Lai Yeung; Bakela Nare; Paul Liberator; Dennis Schmatz
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

3.  JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium.

Authors:  Geoffrey W Birrell; Marina Chavchich; Arba L Ager; Hong-Ming Shieh; Gavin D Heffernan; Wenyi Zhao; Peter E Krasucki; Kurt W Saionz; Jacek Terpinski; Guy A Schiehser; Laura R Jacobus; G Dennis Shanks; David P Jacobus; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

4.  Crystal and molecular structure of the antimalarial agent 4-(tert-butyl)-2-(tert-butylaminomethyl)-6-(4-chlorophenyl)phenol dihydrogen phosphate (WR 194,965 phosphate).

Authors:  J M Karle; I L Karle
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

5.  Arylmethylamino steroids as antiparasitic agents.

Authors:  Reimar Krieg; Esther Jortzik; Alice-Anne Goetz; Stéphanie Blandin; Sergio Wittlin; Mourad Elhabiri; Mahsa Rahbari; Selbi Nuryyeva; Kerstin Voigt; Hans-Martin Dahse; Axel Brakhage; Svenja Beckmann; Thomas Quack; Christoph G Grevelding; Anthony B Pinkerton; Bruno Schönecker; Jeremy Burrows; Elisabeth Davioud-Charvet; Stefan Rahlfs; Katja Becker
Journal:  Nat Commun       Date:  2017-02-17       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.